On February 15, 2022 Paige, the global leader in AI-based diagnostic software in pathology, and Mindpeak, the European leader for AI-based software for image analysis in pathology, reported a distribution partnership, which will enable pathologists to use Mindpeak’s BreastIHC* within the Paige Platform (Press release, Paige AI, FEB 15, 2022, View Source [SID1234608158]). Mindpeak’s BreastIHC is an AI software that reliably and accurately detects, classifies and quantifies breast cancer cells. This partnership enhances the utility of the Paige Platform by providing real-time results for routine breast cancer immunohistochemistry (IHC) biomarkers.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The detection and quantification of IHC markers is an important step in treatment planning for breast cancer. Mindpeak’s BreastIHC is the first-ever plug-and-play AI solution for reliable HER2, Ki-67, estrogen (ER) and progesterone receptor (PR) quantification, without the need for complex set-up and calibration procedures. The product helps to differentiate between tumorous and non-tumorous structures on a single-cell basis, improving the specificity of the scoring.
"By combining MindPeak’s products for IHC with Paige’s AI products for H&E, our partnership will allow pathologists to drive efficient routine clinical cancer diagnostics in breast cancer," said Andy Moye, Ph.D., Chief Executive Officer at Paige. "We are excited to offer Mindpeak’s industry-leading BreastIHC directly within the Paige Platform to improve patient care. We believe integrating our products will drive the adoption of digital pathology technologies more broadly."
Paige Platform is a comprehensive digital pathology software platform that is inclusive of a viewer and storage capabilities and is compatible with existing digital pathology solutions, including most scanners, monitors, and laboratory information systems (LIS).
"This partnership brings us a big step closer to our shared goal of making pathological diagnosis of breast cancer quicker, more accurate and more reproducible," said Felix Faber, CEO at Mindpeak. "I am extremely excited that we will combine our respective strengths in analyzing H&E and IHC-stained tissue samples to make this vision of utilizing AI within pathology a reality."
* Mindpeak’s BreastIHC is available in the EU as a CE-IVD marked medical device. Outside the EU, BreastIHC is Research Use Only, not for use in diagnostic procedures.